BioCentury
ARTICLE | Clinical News

Jardiance empagliflozin: Phase III data

August 24, 2015 7:00 AM UTC

Top-line data from the double-blind, international Phase III EMPA-REG OUTCOME trial in about 7,097 Type II diabetics at a high risk for CV events showed that Jardiance plus standard of care (SOC) met ...